DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells
Open accessPublished version of a preprint
Abstract
Although natural killer (NK) cells are well known for their ability to kill tumors, few studies have addressed the interactions between resting (nonactivated) NK cells and freshly isolated human tumors. Here, we show that human leukocyte antigen class Ilow tumor cells isolated directly from patients with advanced ovarian carcinoma trigger degranulation by resting allogeneic NK cells. This was paralleled by induction of granzyme B and caspase-6 activities in the tumor cells and significant tumor cell lysis. Ovarian carcinoma cells displayed ubiquitous expression of the DNAX accessory molecule-1 (DNAM-1) ligand PVR and sparse/heterogeneous expression of the NKG2D ligands MICA/MICB and ULBP1, ULBP2, and ULBP3. In line with the NK receptor ligand expression profiles, antibody-mediated blockade of activating receptor pathways revealed a dominant role for DNAM-1 and a complementary contribution of NKG2D signaling in tumor cell recognition. These results show that resting NK cells are capable of directly recognizing freshly isolated human tumor cells and identify ovarian carcinoma as a potential target for adoptive NK cell–based immunotherapy. [Cancer Res 2007;67(3):1317–25]
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NKp30, NKp46, and DNAM-1 are NK activation receptors involved in the recognition and lysis of different tumors, such as hematological malignancies, melanoma, and ovarian cancer.
“Moreover, NKp30, NKp46, and DNAM-1 are NK activation receptors involved in the recognition and lysis of different tumors, such as hematological malignancies [82], melanoma [83], and ovarian cancer [84].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · see citing works
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. A. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,000 · see citing works
Lanier, L. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,765 · see citing works
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · see citing works
Self-citationMiller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894 · see citing works
Kiessling, R. W., Klein, E., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050208 · Cited by 1,827 · see citing works
Self-citationBetts, M. R., Brenchley, J. M., Price, D. A., Rosa, S. C. D., Douek, D. C., Roederer, M., & Koup, R. A. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00265-5 · Cited by 1,587 · see citing works
CD107a as a functional marker for the identification of natural killer cell activity
Alter, G., Malenfant, J., & Altfeld, M. A. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.08.008 · Cited by 1,416 · see citing works
Cosman, D. J., Müllberg, J., Sutherland, C. L., Chin, W. A., Armitage, R. J., Fanslow, W. C., Kubin, M. Z., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,228 · see citing works
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J. M., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,181 · see citing works
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030788 · Cited by 874 · see citing works
Bryceson, Y. T., March, M., Ljunggren, H., & Long, E. O. (2005) · Blood · doi:10.1182/blood-2005-04-1351 · Cited by 863 · see citing works
Self-citationPende, D., Parolini, S., Pessino, A. M., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1505 · Cited by 794 · see citing works
Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 745 · see citing works
The Role of the NKG2D Immunoreceptor in Immune Cell Activation and Natural Killing
Jamieson, A. M., Diefenbach, A., McMahon, C. W., Xiong, N., Carlyle, J. R., & Raulet, D. H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00333-3 · Cited by 647 · see citing works
Pessino, A. M., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.953 · Cited by 578 · see citing works
Bryceson, Y. T., March, M., Barber, D. F., Ljunggren, H., & Long, E. O. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051143 · Cited by 494 · see citing works
Self-citationPende, D., Spaggiari, G. M., Marcenaro, S., Martini, S., Rivera, P., Capobianco, A., Falco, M., Lanino, E., Pierri, I., Zambello, R., et al. (2004) · Blood · doi:10.1182/blood-2004-09-3548 · Cited by 368 · see citing works
Fuchs, A. G., Cella, M., Giurisato, E., Shaw, A. S., & Colonna, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3994 · Cited by 358 · see citing works
Carbone, E. (2004) · Blood · doi:10.1182/blood-2004-04-1422 · Cited by 333 · see citing works
Passweg, J. R., Tichelli, A., Meyer‐Monard, S., Heim, D. A., Stern, M., Kühne, T., Favre, G., & Gratwohl, A. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403524 · Cited by 269 · see citing works
Natural Killer Cell-Mediated Killing of Freshly Isolated Neuroblastoma Cells
Castriconi, R., Dondero, A., Corrias, M. V., Lanino, E., Pende, D., Moretta, L., Bottino, C., & Moretta, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2682 · Cited by 257 · see citing works
Lai, P., Rabinowich, H., Crowley‐Nowick, P. A., Bell, M. C., Mantovani, G., & Whiteside, T. L. (1996) · PubMed · Cited by 218 · see citing works
Malmberg, K., Levitsky, V., Norell, H., de Matos, C. T., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15564 · Cited by 180 · see citing works
Self-citationNK cell recognition of non-classical HLA class I molecules
López‐Botet, M., Llano, M., Navarro, F., & Bellón, T. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0213 · Cited by 179 · see citing works
The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance
Fuchs, A. G., & Colonna, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.002 · Cited by 168 · see citing works
Liu, L., Chahroudi, A., Silvestri, G., Wernett, M. E., Kaiser, W. J., Safrit, J. T., Komoriya, A., Altman, J. D., Packard, B. Z., & Feinberg, M. B. (2002) · Nature Medicine · doi:10.1038/nm0202-185 · Cited by 162 · see citing works
Pende, D., Bottino, C., Castriconi, R., Cantoni, C., Marcenaro, S., Rivera, P., Spaggiari, G. M., Dondero, A., Carnemolla, B., Reymond, N., et al. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.028 · Cited by 152 · see citing works
Malmberg, K., Levitsky, V., Norell, H., de Matos, C. T., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215564 · Cited by 151 · see citing works
Self-citationEffective immunotherapy against cancer
Malmberg, K. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0577-x · Cited by 144 · see citing works
Self-citationWang, P. L., O'Farrell, S., Clayberger, C., & Krensky, A. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.8.2600 · Cited by 139 · see citing works
Vitale, M., Pelusi, G., Taroni, B., Gobbi, G., Micheloni, C., Rezzani, R., Donato, F., Wang, X., & Ferrone, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.67.11.1 · Cited by 113 · see citing works
HLA class I recognition by killer cell Ig-like receptors
Long, E. O., & Rajagopalan, S. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0212 · Cited by 94 · see citing works
Escape from immune- and nonimmune-mediated tumor surveillance
Malmberg, K., & Ljunggren, H. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.007 · Cited by 76 · see citing works
Self-citationNorell, H., Carlsten, M., Ohlum, T., Malmberg, K., Masucci, G. V., Schedvins, K., Altermann, W., Handke, D., Atkins, D., Seliger, B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0029 · Cited by 67 · see citing works
Self-citationRecombinant IL‐2‐activated NK cells mediate LAK activity against ovarian cancer
Lotzová, E., Savary, C. A., Freedman, R. S., Edwards, C. L., & Wharton, J. T. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420214 · Cited by 29 · see citing works
Lai, P., Rabinowich, H., Crowley‐Nowick, P. A., Bell, M. C., Mantovani, G., & Whiteside, T. L. (1997) · Biochemical Society Transactions · doi:10.1042/bst025218s · Cited by 24 · see citing works
Natural immunity against ovarian tumors
Lotzová, E., Savary, C. A., Freedman, R. S., & BOWEN, J. (1986) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/0147-9571(86)90021-4 · Cited by 17 · see citing works
Natural killer cell activity in patients with ovarian tumors and uterine myomas.
Roszkowski, P. I., Hyc, A., & Malejczyk, J. (1993) · PubMed · Cited by 16 · see citing works
Bokhman, J. B., & Maximov, S. (1993) · PubMed · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Long, E. O., Kim, H. S., Liu, D., Peterson, M., & Rajagopalan, S. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075005 · Cited by 1,209 · see citing works
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H., & Bryceson, Y. T. (2009) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 894 · see citing works
Self-citationNK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682 · see citing works
Solana, R., Tarazona, R., Gayoso, I., Lesur, O., Dupuis, G., & Fulop, T. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.04.008 · Cited by 567 · see citing works
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H., & Malmberg, K. (2007) · Nature reviews. Immunology · doi:10.1038/nri2073 · Cited by 538 · see citing works
Self-citationImmunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510 · see citing works
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460 · see citing works
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R. G., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis‐Mortari, A., Curtsinger, J., McKenna, D. H., et al. (2010) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 436 · see citing works
TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy
Dougall, W. C., Kurtuluş, S., Smyth, M. J., & Anderson, A. C. (2017) · Immunological Reviews · doi:10.1111/imr.12518 · Cited by 432 · see citing works
NKG2D ligands in tumor immunity
Nausch, N., & Cerwenka, A. (2008) · Oncogene · doi:10.1038/onc.2008.272 · Cited by 409 · see citing works
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature reviews. Immunology · doi:10.1038/nri2604 · Cited by 396 · see citing works
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C. M., Howard, E. D., Chadwick, E. M., Johnston, J. V., Hammond, A. J., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 358 · see citing works
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36022 · Cited by 347 · see citing works
El-Sherbiny, Y. M., Meade, J. L., Holmes, T. D., McGonagle, D. G., Mackie, S. L., Morgan, A. W., Cook, G., Feyler, S., Richards, S. J., Davies, F. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4230 · Cited by 320 · see citing works
Natural killer cell-mediated immunosurveillance of human cancer
Malmberg, K., Carlsten, M., Björklund, A. T., Sohlberg, E., Bryceson, Y. T., & Ljunggren, H. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.002 · Cited by 301 · see citing works
Self-citationAccelerated tumor growth in mice deficient in DNAM-1 receptor
Iguchi‐Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara‐Hanaoka, S., Honda, S.-I., Yasui, T., Kikutani, H., Shibuya, K., & Shibuya, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081611 · Cited by 289 · see citing works
Carlsten, M., Norell, H., Bryceson, Y. T., Poschke, I. C., Schedvins, K., Ljunggren, H., Kiessling, R. W., & Malmberg, K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901226 · Cited by 283 · see citing works
Self-citationMandal, A., & Viswanathan, C. (2014) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2014.11.006 · Cited by 271 · see citing works
Tallerico, R., Todaro, M., Franco, S. D., Maccalli, C., Garofalo, C., Sottile, R., Palmieri, C., Tirinato, L., Pangigadde, P., Rocca, R. L., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201542 · Cited by 251 · see citing works
Correia, D. V., Fogli, M., Hudspeth, K. L., da Silva, M. G., Mavilio, D., & Silva‐Santos, B. (2011) · Blood · doi:10.1182/blood-2011-02-339135 · Cited by 236 · see citing works
Decreased expression of DNAM‐1 on NK cells from acute myeloid leukemia patients
Sanchez‐Correa, B., Gayoso, I., Bergua, J. M., Casado, J. G., Morgado, S., Solana, R., & Tarazona, R. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.15 · Cited by 228 · see citing works
NKG2D ligands as therapeutic targets.
(2013) · Europe PMC (PubMed Central) · Cited by 218 · see citing works
Sánchez-Correa, B., Valhondo, I., Hassouneh, F., López-Sejas, N., Pera, A., Bergua, J., Arcos, M. J., Bañas, H., Casas-Avilés, I., Durán, E., et al. (2019) · Cancers · doi:10.3390/cancers11060877 · Cited by 210 · see citing works
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Gubbels, J. A. A., Felder, M. A. R., Horibata, S., Belisle, J. A., Kapur, A., Holden, H., Petrie, S. E., Migneault, M., Rancourt, C., Connor, J. P., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-11 · Cited by 211 · see citing works
Samanta, D., & Almo, S. C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1763-4 · Cited by 209 · see citing works
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 202 · see citing works
Alici, E., Sütlü, T., Björkstrand, B., Gilljam, M., Stellan, B., Nahi, H., Quezada, H. C., Gahrton, G., Ljunggren, H., & Dilber, M. S. (2008) · Blood · doi:10.1182/blood-2007-09-110312 · Cited by 197 · see citing works
Self-citationBeyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
Mercier, I. L., Lines, J. L., & Noelle, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00418 · Cited by 196 · see citing works
Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita∥, H., Gilfillan, S., Colonna, M., & Smyth, M. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0903225 · Cited by 181 · see citing works
B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
Pesce, S., Tabellini, G., Cantoni, C., Patrizi, O., Coltrini, D., Rampinelli, F., Matta, J., Vivier, É., Moretta, A., Parolini, S., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1001224 · Cited by 178 · see citing works
Wilson, E., El‐Jawhari, J. J., Neilson, A. L., Hall, G. D., Melcher, A. A., Meade, J. L., & Cook, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022842 · Cited by 174 · see citing works
Targeting PVR (CD155) and its receptors in anti-tumor therapy
Brlić, P. K., Roviš, T. L., Cinamon, G., Tsukerman, P., Mandelboim, O., & Jonjić, S. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0168-y · Cited by 169 · see citing works
Use of Allogeneic NK Cells for Cancer Immunotherapy
Geller, M. A., & Miller, J. S. (2011) · Immunotherapy · doi:10.2217/imt.11.131 · Cited by 163 · see citing works
Neuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells
Castriconi, R., Dondero, A., Bellora, F., Moretta, L., Castellano, A., Locatelli, F., Corrias, M. V., Moretta, A., & Bottino, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202693 · Cited by 159 · see citing works
Mincheva‐Nilsson, L., & Baranov, V. I. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.02.010 · Cited by 141 · see citing works
Casado, J. G., Pawelec, G., Morgado, S., Sánchez-Correa, B., Delgado, E., Gayoso, I., Durán, E., Solana, R., & Tarazona, R. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0682-y · Cited by 140 · see citing works
Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients
Rocca, Y., Roberti, M. P., Arriaga, J. M., Amat, M., Bruno, L. I., Pampena, M. B., Huertas, E., Loria, F. S., Pairola, A., Bianchini, M., et al. (2012) · Innate Immunity · doi:10.1177/1753425912453187 · Cited by 138 · see citing works
IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
Felices, M., Chu, S., Kodal, B., Bendzick, L. E., Ryan, C. J., Lenvik, A. J., Boylan, K. L. M., Wong, H. C., Skubitz, A. P. N., Miller, J. S., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.02.028 · Cited by 136 · see citing works
Toutirais, O., Cabillic, F., Friec, G. L., Salot, S., Loyer, P., Gallo, M. L., Desille, M., Pintière, C. T. D. L., Daniel, P., Bouet, F., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200838409 · Cited by 132 · see citing works
Baci, D., Bosi, A., Gallazzi, M., Rizzi, M., Noonan, D. M., Poggi, A. D., Bruno, A., & Mortara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093125 · Cited by 130 · see citing works
Matusali, G., Potestà, M., Santoni, A., Cerboni, C., & Doria, M. (2012) · Journal of Virology · doi:10.1128/jvi.05788-11 · Cited by 129 · see citing works
Human Vγ9Vδ2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts
Gertner-Dardenne, J., Castellano, R., Mamessier, É., Garbit, S., Kochbati, E., Etienne, A., Charbonnier, A., Collette, Y., Vey, N., & Olive, D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103710 · Cited by 128 · see citing works
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways
Verhoeven, D. H. J., de Hooge, A. S. K., Mooiman, E., Santos, S. J., ten Dam, M. M., Gelderblom, H. A. J., Melief, C. J. M., Hogendoorn, P. C. W., Egeler, R. M., van Tol, M. J. D., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.016 · Cited by 125 · see citing works
Kim, H. S., Das, A., Groß, C. C., Bryceson, Y. T., & Long, E. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.02.004 · Cited by 124 · see citing works
Self-citationComing of Age: CD96 Emerges as Modulator of Immune Responses
Georgiev, H., Ravens, I., Papadogianni, G., & Bernhardt, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01072 · Cited by 115 · see citing works
CD155: A Multi-Functional Molecule in Tumor Progression
Molfetta, R., Zitti, B., Lecce, M., Milito, N. D., Stabile, H., Fionda, C., Cippitelli, M., Gismondi, A., Santoni, A., & Paolini, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030922 · Cited by 113 · see citing works
Increased Soluble CD155 in the Serum of Cancer Patients
Iguchi‐Manaka, A., Okumura, G., Kojima, H., Cho, Y., Hirochika, R., Bando, H., Sato, T., Yoshikawa, H., Hara, H., Shibuya, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152982 · Cited by 113 · see citing works
New views on natural killer cell-based immunotherapy for melanoma treatment
Burke, S., Lakshmikanth, T., Colucci, F., & Carbone, E. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.003 · Cited by 107 · see citing works
Bottino, C., Dondero, A., Bellora, F., Moretta, L., Locatelli, F., Pistoia, V., Moretta, A., & Castriconi, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00056 · Cited by 105 · see citing works
Chiang, E. Y., de Almeida, P. E., Nagata, D. D. A., Bowles, K. H., Du, X., Chitre, A. S., Banta, K. L., Kwon, Y. C., McKenzie, B. S., Mittman, S., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.201948405 · Cited by 103 · see citing works
CD226: An Emerging Role in Immunologic Diseases
Huang, Z., Qi, G., Miller, J. S., & Zheng, S. G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00564 · Cited by 103 · see citing works
Vito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 102 · see citing works
Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells
Enqvist, M., Ask, E. H., Forslund, E., Carlsten, M., Abrahamsen, G., Béziat, V., Andersson, S., Schaffer, M., Spurkland, A., Bryceson, Y. T., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401972 · Cited by 100 · see citing works
Self-citationThe murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1
Seth, S., Maier, M. K., Qiu, Q., Ravens, I., Kremmer, E., Förster, R., & Bernhardt, G. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.102 · Cited by 99 · see citing works
Ni, Z., Knorr, D. A., Bendzick, L. E., Allred, J. R., & Kaufman, D. S. (2013) · Stem Cells · doi:10.1002/stem.1611 · Cited by 97 · see citing works
Ni, Z., Knorr, D. A., Clouser, C. L., Hexum, M. K., Southern, P. J., Mansky, L. M., Park, I., & Kaufman, D. S. (2010) · Journal of Virology · doi:10.1128/jvi.01774-10 · Cited by 97 · see citing works
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 93 · see citing works
Labani‐Motlagh, A., Israelsson, P., Ottander, U., Lundin, E., Nagaev, I., Nagaeva, O., Dehlin, E., Baranov, V. I., & Mincheva‐Nilsson, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-4313-2 · Cited by 93 · see citing works
A robust platform for expansion and genome editing of primary human natural killer cells
Huang, R., Lai, M., Shih, H.-A., & Lin, S. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201529 · Cited by 91 · see citing works
Cluxton, C. D., Spillane, C. D., O’Toole, S. A., Sheils, O. M., Gardiner, C. M., & O’Leary, J. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211538 · Cited by 90 · see citing works
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg, K., Bryceson, Y. T., Carlsten, M., Andersson, S., Björklund, A. T., Björkström, N. K., Baumann, B. C., Fauriat, C., Alici, E., Dilber, M. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0492-7 · Cited by 89 · see citing works
Self-citationPreclinical and clinical studies of CAR-NK-cell therapies for malignancies
Li, H., Song, W., Li, Z., & Zhang, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992232 · Cited by 88 · see citing works
Barber, A. E., Zhang, T., & Sentman, C. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.72 · Cited by 83 · see citing works
NK Cell Therapy: A Rising Star in Cancer Treatment
Du, N., Guo, F., Wang, Y., & Cui, J. (2021) · Cancers · doi:10.3390/cancers13164129 · Cited by 83 · see citing works
Matuszewska, K., Santry, L. A., van Vloten, J. P., AuYeung, A. W. K., Major, P. P., Lawler, J., Wootton, S. K., Bridle, B. W., & Petrik, J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0220 · Cited by 82 · see citing works
Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials
Suen, C.-W. W., Lee, W., Leung, K. T., Pan, X., & Li, G. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1515315 · Cited by 80 · see citing works
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
Palaia, I., Tomao, F., Sassu, C. M., Musacchio, L., & Panici, P. B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s205950 · Cited by 83 · see citing works
Newtonian cell interactions shape natural killer cell education
Goodridge, J. P., Önfelt, B., & Malmberg, K. (2015) · Immunological Reviews · doi:10.1111/imr.12325 · Cited by 74 · see citing works
Self-citationGeller, M. A., Knorr, D. A., Hermanson, D., Pribyl, L. J., Bendzick, L. E., McCullar, V., Miller, J. S., & Kaufman, D. S. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.05.022 · Cited by 73 · see citing works
Maas, R. J. A., Evert, J. S. H., der Meer, J. M. R. V., Mekers, V. E., Rezaeifard, S., Korman, A. J., de Jonge, P. K. J. D., Cany, J., Woestenenk, R., Schaap, N. P., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1843247 · Cited by 69 · see citing works
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
Buckle, I., & Guillerey, C. (2021) · Cancers · doi:10.3390/cancers13174263 · Cited by 71 · see citing works
Giamougiannis, P., Martin‐Hirsch, P. L., & Martin, F. L. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab010 · Cited by 71 · see citing works
Gavalas, N. G., Karadimou, A., Dimopoulos, M. A., & Bamias, A. (2010) · Journal of Immunology Research · doi:10.1155/2010/791603 · Cited by 66 · see citing works
Dupuy, S., Lambert, M., Zucman, D., Choukem, S. P., Tognarelli, S., Pagès, C., Lebbé, C., & Caillat‐Zucman, S. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002486 · Cited by 64 · see citing works
Kearney, C. J., Ramsbottom, K. M., Voskoboinik, I., Darcy, P. K., & Oliaro, J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196308 · Cited by 64 · see citing works
Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
Gorvel, L., & Olive, D. (2020) · F1000Research · doi:10.12688/f1000research.22877.1 · Cited by 65 · see citing works
Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Zhao, X., Yu, Y., Zhang, H., Xu, F., & Tian, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02068-5 · Cited by 63 · see citing works
Multi-omics characterization of silent and productive HPV integration in cervical cancer
Fan, J., Fu, Y., Peng, W., Li, X., Shen, Y., Guo, E., Lu, F., Zhou, S., Liu, S., Yang, B., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2022.100211 · Cited by 61 · see citing works
Wennerberg, E., Pfefferle, A., Ekblad, L., Yoshimoto, Y., Kremer, V., Kaminskyy, V. O., Juhlin, C. C., Höög, A., Bodin, I., Svjatoha, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0291 · Cited by 61 · see citing works
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 60 · see citing works
DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses
Shibuya, A., & Shibuya, K. (2021) · International Immunology · doi:10.1093/intimm/dxab085 · Cited by 60 · see citing works
Ren, X., Peng, M., Peng, X., Yao, W., Galbo, P. M., Corrigan, D. T., Wang, H., Su, Y., Dong, X., Sun, Q., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163620 · Cited by 55 · see citing works
Gong, J.-Y., Fang, L., Liu, R., Wang, Y., Xing, J., Chen, Y.-B., Zhuang, R., Zhang, Y., Zhang, C.-M., Yang, A., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201444574 · Cited by 50 · see citing works
Bae, D. S., & Lee, J. K. (2014) · Blood Research · doi:10.5045/br.2014.49.3.154 · Cited by 55 · see citing works
NK cell-based cancer immunotherapy: from basic biology to clinical application
Li, Y., Yin, J., Li, T., Huang, S., Yan, H., Leavenworth, J. W., & Wang, X. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4970-9 · Cited by 55 · see citing works
Poznanski, S. M., Nham, T., Chew, M. V., Lee, A. J., Hammill, J. A., Fan, I. Y., Butcher, M. K., Bramson, J. L., Lee, D. A., Hirte, H. W., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0144 · Cited by 54 · see citing works
Beck, R. C., Padival, M., Yeh, D., Ralston, J., Cooke, K. R., & Lowe, J. B. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.06.002 · Cited by 52 · see citing works
Immunosenescence: limitations of natural killer cell-based cancer immunotherapy
Tarazona, R., Sánchez-Correa, B., Casas-Avilés, I., Campos, C., Pera, A., Morgado, S., López-Sejas, N., Hassouneh, F., Bergua, J., Arcos, M. J., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1882-x · Cited by 52 · see citing works
Enqvist, M., Nilsonne, G., Hammarfjord, O., Wallin, R. P. A., Björkström, N. K., Björnstedt, M., Hjerpe, A., Ljunggren, H., Dobra, K., Malmberg, K., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100610 · Cited by 51 · see citing works
Self-citationTissue‐specific effector functions of innate lymphoid cells
Björkström, N. K., Kekäläinen, E., & Mjösberg, J. (2013) · Immunology · doi:10.1111/imm.12098 · Cited by 48 · see citing works
Marrella, A., Dondero, A., Aiello, M., Casu, B., Olive, D., Regis, S., Bottino, C., Pende, D., Meazza, R., Caluori, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01876 · Cited by 48 · see citing works
Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis
Alteber, Z., Kotturi, M. F., Whelan, S., Ganguly, S., Weyl, E., Pardoll, D. M., Hunter, J., & Ophir, E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1248 · Cited by 48 · see citing works
TGF-beta: a master switch in tumor immunity
Gigante, M., Gesualdo, L., & Ranieri, E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802430378 · Cited by 45 · see citing works
NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer
Leung, E. Y. L., Ennis, D. P., Kennedy, P. R., Hansell, C. A. H., Dowson, S., Farquharson, M., Spiliopoulou, P., Nautiyal, J., McNamara, S., Carlin, L. M., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.02.001 · Cited by 46 · see citing works
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
Zitti, B., Molfetta, R., Fionda, C., Quatrini, L., Stabile, H., Lecce, M., de Turris, V., Ricciardi, M. R., Petrucci, M. T., Cippitelli, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10403-0 · Cited by 44 · see citing works
Hou, S., Ge, K., Zheng, X., Wei, H., Sun, R., & Tian, Z. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498253 · Cited by 43 · see citing works
Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki, T., Onishi, H., & Katano, M. (2012) · PubMed · Cited by 43 · see citing works
Stegmann, K. A., Björkström, N. K., Ciesek, S., Lunemann, S., Jaroszewicz, J., Wiegand, J., Malinski, P., Dustin, L. B., Rice, C. M., Manns, M. P., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis210 · Cited by 42 · see citing works
Self-citationStamm, H., Wellbrock, J., & Fiedler, W. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9770-7 · Cited by 41 · see citing works
Molfetta, R., Milito, N. D., Zitti, B., Lecce, M., Fionda, C., Cippitelli, M., Santoni, A., & Paolini, R. (2018) · European Journal of Immunology · doi:10.1002/eji.201847848 · Cited by 39 · see citing works
- Authors
- Carlsten, M., Björkström, N. K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B. C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.-G., & Malmberg, K.-J.
- Affiliations
- Karolinska University Hospital (SE)
- 1Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge;
- 2Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Department of Oncology and Pathology, Karolinska Institutet;
- Karolinska Institutet (SE)
- Venue
- Cancer Research
- Published
- 2007-02-01
- Volume
- 67
- Issue
- 3
- Pages
- 1317-1325
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2104794630
- Cited by
- 234
- References
- 40
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 8 · 2023: 10 · 2022: 7 · 2021: 14 · 2020: 18 · 2019: 11 · 2018: 16 · 2017: 14 · 2016: 11 · 2015: 14 · 2014: 14 · 2013: 14 · 2012: 14
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Foundation
- Stiftelsen för Strategisk Forskning
- Cancerfonden
- Svenska Sällskapet för Medicinsk Forskning
- Karolinska Institutet
- Vetenskapsrådet
- National Institutes of Health
- National Cancer Institute (R01CA102280, CA 102280)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Keywords
- DNAM-1, PVR, NKG2D, ovarian carcinoma, NK cell degranulation, granzyme B, caspase-6, ULBP, tumor cell lysis, NK cell therapy, cancer cell detection
- MeSH terms
- T Lineage-Specific Activation Antigen 1, Antigens, Differentiation, T-Lymphocyte, Female, Humans, Killer Cells, Natural, Ligands, Ovarian Neoplasms, Receptors, Immunologic, Cell Degranulation, K562 Cells, Granzymes, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
